This is an excellent presentation with some very useful info not previously announced, such as:
How to interpret phase 2 results
Page 4 - to be considered a great clinical outcome, phase 2a just needs 25% of patients to show a significant reduction in proteinuria.
Peer comparison
Page 11 - showing how ridiculous the current market cap is when compared to similar companies on the ASX and NASDAQ.
Acquisition of company similar to Dimerix
Page 9 - a new acquisition occurred a few days ago where a company in phase 2a providing GPCR services (similar to Dimerix) was acquired for EUR500m upfront plus EUR300m potential milestone payments.
Also a pretty big statement on page 8 "Global pharmaceutical companies need access to Dimerix’s Receptor-HIT technology to develop safe new drugs"
Ann: Investor Update, page-2
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $225.5M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 41.8¢ | 40.0¢ | $776.3K | 1.907M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 111946 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 20706 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |